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Abstract
Objectives. The aim was to define clinical characteristics and long-term survival of patients with
dcSSc and positive ACA.
Methods. We identified all cases of ACAþ SSc in our cohort (n¼ 1313). Those with dcSSc (ACAþ dif-
fuse) were compared with representative groups of consecutive ACAþ patients with limited subset
(ACAþ limited) and ACA dcSSc (non-ACA diffuse).
Results. Thirty-five patients (2.7%) were ACAþ diffuse. The peak modified Rodnan skin score was not
significantly different between the dcSSc subgroups, but it occurred later in the disease course in
ACAþ diffuse (88.54 vs 30.65 months, P< 0.001). Patterns of organ involvement were different between
the groups. ACAþ diffuse had a higher incidence of interstitial lung disease than ACAþ limited (22.86
vs 4.43%, P¼ 0.001), but lower than non-ACA diffuse (41.18%, P¼ 0.042). More patients developed
pulmonary hypertension in the ACAþ diffuse group (28.5 vs 12.0% ACAþ limited or 12.0% non-ACA
diffuse), although this was attributable to the longer follow-up in these patients. The cumulative inci-
dence of pulmonary hypertension was not different from the other two groups. The incidence of
cardiac involvement was similar between the dcSSc groups, and scleroderma renal crisis was more
frequent in the non-ACA diffuse group. Survival in ACAþ patients was similar in both subsets, whereas
non-ACA diffuse had higher mortality.
Conclusion. ACAþ dcSSc is uncommon and has a distinct clinical phenotype, with a more insidious
onset of skin and organ involvement. Even in dcSSc, ACA appears protective for organ-based compli-
cations, namely interstitial lung disease and scleroderma renal crisis, and is associated with a better
survival than expected in dcSSc.
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Introduction
Although the pathogenic role of autoantibodies in sclero-
derma (SSc) is still unclear, there is strong evidence of a
link between autoantibodies and organ complications
and survival [1]. ACAs are the most frequent autoanti-
bodies in SSc and are described as protective for
Key messages
. Although uncommon, ACAþ diffuse patients have a distinct clinical phenotype.
. ACA, or factors determining its development, may act as a phenotype modifier in diffuse SSc.
. Awareness of the trajectory of organ involvement in this subset may facilitate timely therapeutic interventions.
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scleroderma renal crisis (SRC) and interstitial lung dis-
ease (ILD) [2]. ACAs are typically associated with lcSSc,
although a small proportion of ACAþ patients (5–7%),
will have the diffuse cutaneous subset (dSSc) [2–4].
Both antibody specificity and disease subset may influ-
ence disease phenotypic expression and organ manifes-
tations. Extensive skin involvement has been associated
with more frequent internal organ involvement, mainly
SRC and ILD, and with decreased survival in
comparison with lcSSc [1, 5, 6].
The purpose of our study was to describe the clinical
manifestations and long-term survival of ACAþ SSc
patients with diffuse skin involvement (ACAþ diffuse),
compared with two other subsets: ACAþ patients with
lcSSc (ACAþ limited) and ACA with dcSSc (non-ACA
diffuse). Our hypothesis is that ACAþ diffuse is a sub-
group of SSc with distinct clinical manifestations.
Materials and methods
Study cohort
We identified all ACAþ SSc patients evaluated at the
Centre for Rheumatology and Connective Tissue
Diseases at the Royal Free Hospital between 2001 and
2015 (n¼1313). Of those, all consecutive ACAþ patients
with dcSSc subset were selected (n¼ 35). Cutaneous
involvement was defined as diffuse if skin thickening
affected both distal and proximal areas to the elbows
and knees, and as limited if skin thickening did not
affect proximal areas. Comparative groups were defined
as follows: 158 consecutive ACAþ limited and 258 con-
secutive non-ACA diffuse patients, from a well-
characterized population of our SSc database. Patients
without a fully established characterization were not
included in the analysis as a comparison group.
Comprehensive data were obtained from the Royal Free
Hospital research database and integrated medical
records review. All study patients fulfilled the 2013 ACR/
EULAR classification criteria for SSc [7]. All procedures
performed were in accordance with the ethical stand-
ards of the institutional research committee and with the
1964 Declaration of Helsinki and its later amendments,
and informed consent was obtained from all study
participants.
Autoantibodies were measured in an accredited institu-
tional autoimmune serology laboratory using a validated
in-house assay with appropriate quality control and
blinded assessment of the results at time of reading. In
brief, ANAs were identified by IIF on HEp-2 cell substrate,
considered positive if titre 1/100; ACA and anti-U3-RNP
were identified by indirect IIF on HEp-2 cell substrate;
anti-Scl70, -nRNP, -Pm-Scl, -La and -Ro were identified
by IIF and counter-immunoelectrophoresis; and anti-RNA
polymerase III were identified by IIF and ELISA.
Clinical manifestations were recorded based on the
assessment of the latest clinic visit. We used definitions
of moderate-to-severe organ-based complications of SSc
defined in previous studies [8]. SRC was defined as new
onset of systemic hypertension >150/85 mmHg and a
decrease in estimated glomerular filtration rate 30%, or
SRC features in a renal biopsy. Pulmonary hypertension
(PH) was defined as right heart catheterization with a
mean pulmonary artery pressure of 25 mmHg and a
normal pulmonary capillary wedge pressure. This included
patients with CTD-associated pulmonary arterial hyperten-
sion and PH associated with ILD. ILD was confirmed by
the presence of ground-glass opacities and/or honey-
combing on high-resolution chest tomography, and clini-
cally significant if forced vital capacity (FVC) or diffusing
capacity for carbon monoxide (DLCO)55% predicted or
a documented decline in FVC or DLCO of 15%. Cardiac
involvement was defined as haemodynamically significant
cardiac arrhythmias, pericardial effusion or congestive
heart failure requiring specific treatment in the absence of
other known cardiac causes.
Disease onset was defined as the time since the first
reported non-RP manifestation of SSc. Peak modified
Rodnan skin score (mRSS) was defined as the highest
mRSS recorded since disease onset and the latest clinic
visit. Time to internal organ complications and time to
death were defined as the time in months since SSc
onset and the time point when the definition for signifi-
cant organ involvement was fulfilled.
Statistical analysis
Student’s t-test and Fisher’s exact test were used to
compare demographic and clinical characteristics.
Kaplan–Meier estimates of survival and 1Kaplan–
Meier estimates of cumulative incidence of organ com-
plications were calculated, and the log-rank test was
used to compare those between the three groups.
Analysis was carried out using STATA 14.
Results
Demographic and clinical characteristics
From a total of 1313 identified ACAþ SSc patients, 35
(2.7%) had the diffuse cutaneous subset. Table 1 shows
the demographic, clinical characteristics and autoanti-
bodies of the three groups.
At disease onset, patients with lcSSc were older than
patients with dcSSc (P< 0.001). On average, peak
mRSS was slightly higher in the non-ACA diffuse group
(27 6 10) compared with the ACAþ diffuse patients
(24 6 10, P¼ 0.075). In addition, ACAþ diffuse patients
reached peak mRSS later in the disease course
(on average, 89 6 78 months from disease onset) com-
pared with non-ACA diffuse patients (31 6 33 months,
P<0.001).
Patterns of internal organ involvement were different
in the three groups (Table 1). Over the entire follow-up
period, the ACAþ diffuse patients had a higher incidence
of ILD (22.9%) compared with ACAþ limited patients
(4.4%, P¼ 0.001), but lower than non-ACA diffuse
patients (41.2%, P¼0.042). Likewise, the incidence of
SRC was higher in ACAþ diffuse subjects (5.7%) com-
pared with none among the ACAþ limited ones, but mar-
ginally lower than that among non-ACA diffuse subjects
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(14%, P¼ 0.280). One of the ACAþ diffuse patients who
had an SRC carried a coexisting anti-RNA polymerase
III antibody.
More patients developed PH in the ACAþ diffuse
group (29%) than in the other two groups (12% in both,
P¼0.036).
Cardiac involvement was similar in both dcSSc
groups (6.2% in the non-ACA diffuse vs 8.6% in the
ACAþ diffuse patients, P¼ 0.484), but much less fre-
quent in ACAþ limited patients (1.9% in this group,
P¼0.074 from comparison with ACAþ diffuse).
Survival analysis
Survival among the ACAþ patients was similar for both
subsets, with 5-, 10- and 15-year survival rates of 96,
85 and 74% in ACAþ limited, and 94, 79 and 71% in
ACAþ diffuse, respectively (P¼ 0.991). In contrast, non-
ACA diffuse patients had much higher mortality, with 5-,
10- and 15-year survival rates of 84, 72 and 55%,
respectively, although the difference from ACAþ diffuse
was not statistically significant (P¼0.165; Fig. 1A). As
expected, ACAþ limited patients had significantly better
survival compared with non-ACA diffuse patients
(P¼0.002).
The incidence of ILD was significantly different
between the three groups (P< 0.001). During follow-up
at 5 years, 15% of ACAþ diffuse patients developed
ILD, compared with 3% of ACAþ limited and 36% of
non-ACA diffuse. At 15 years, the cumulative incidence
of ILD was 27% in ACAþ diffuse, 5% in ACAþ limited
and 50% in non-ACA diffuse patients (Fig. 1B). The
cumulative incidence of ILD in ACAþ diffuse patients
was sustained over a prolonged period beyond 10 years
of the disease course, compared with the non-ACA dif-
fuse group (Fig. 1B).
The cumulative incidence of PH in ACAþ diffuse was
not different from the other two groups (P¼0.621). At 5
years, 9% of ACAþ diffuse patients had developed PH,
compared with 5% in ACAþ limited and 6% in non-ACA
diffuse group, and at 15 years the cumulative incidence
was 27, 19 and 18%, respectively (Fig. 1C).
The cumulative incidence of SRC was higher in the
non-ACA diffuse group (14 and 15% at 5 and 15 years,
respectively) compared with the ACAþ diffuse (3 and
6% at 5 and 15 years, respectively; P¼0.168; Fig. 1D).
The cumulative incidence of cardiac involvement was
similar in both diffuse groups. At 5 years, 9% of the
ACAþ diffuse had cardiac involvement compared with
6% of the non-ACA diffuse, and at 15 years it was still
9% in the ACAþ diffuse group, whereas it was 7% in
non-ACA diffuse. The cumulative incidence of cardiac
disease was lower in ACAþ limited (1% at 5 years and
3% at 15 years, P¼ 0.065).
In our cohort of ACAþ diffuse patients, five harboured
autoantibodies that are typically associated with the dif-
fuse subset [antitopoisomerase (ATA), anti-RNA poly-
merase III (ARA) and anti-U3-RNP antibody; Table 1].
Sensitivity analysis excluding those five patients did not
significantly change the results.
Survival rates were not significantly different between
ACAþ patients with both skin subtypes: 5-, 10- and
15-year survival rates were 96, 84 and 73%,
TABLE 1 Demographic, serological and clinical characteristics of the three groups
ACA1 diffuse, ACA1 limited, Non-ACA diffuse, P-value
n 5 35 n 5 158 n 5 258
Male, n (%) 6 (17.1) 14 (8.9) 55 (21.3) 0.003
Follow-up, mean (S.D.), months 172 (89) 124 (39) 104 (48) <0.001
Age at disease onset, mean (S.D.), years 47 (11) 53 (13) 46 (13) <0.001
Autoantibodies, n (%)
Anti-Scl70 3 (8.6) 1 (0.6) 84 (32.6)
Anti-RNA polymerase III 1 (2.9) – 62 (24.0)
Anti-nRNP 3 (8.6) – 12 (4.6)
Anti-U3-RNP 1 (2.9) – 17 (6.6)
Anti-Ro 1 (2.9) 3 (1.9) 9 (3.5)
Anti-La – 1 (0.6) 2 (0.8)
Anti-Pm-Scl – – 14 (5.4)
ANA negative – – 9 (3.5)
ANA positive, ENA negative – – 54 (20.9)
Peak mRSS, mean (S.D.) 24 (10) 7 (4) 27 (10) <0.001
Time to peak mRSS, mean (S.D.), months 89 (78) 57 (43) 31 (33) <0.001
Interstitial lung disease, n (%) 8 (22.9) 7 (4.4) 105 (41.9) <0.001
Pulmonary hypertension, n (%) 10 (28.6) 19 (12.0) 31 (12.0) 0.036
Cardiac scleroderma, n (%) 3 (8.6) 3 (1.9) 16 (6.2) 0.052
Scleroderma renal crisis, n (%) 2 (5.7) 0 (0) 36 (13.9) <0.001
The incidence of specific internal organ complications is based on the entire follow-up period. P-values are obtained from
global comparison tests; ANOVA for the continuous variables and Fisher’s exact test for categorical variables. mRSS:
modified Rodnan skin score.
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respectively, for ACAþ limited and 96, 78 and 73%,
respectively, for ACAþ diffuse (P¼0.86). Non-ACA dif-
fuse also had lower survival rates than ACAþ diffuse (84,
72 and 65% at 5, 10 and 15 years, respectively),
although it was still not significantly different (P¼ 0.15).
The cumulative incidence of ILD remained different
between the three groups (P<0.001). In the ACAþ dif-
fuse it reduced when dual antibody patients were
excluded to 10% at 15 years, although it remained
higher than that in the ACAþ limited (5% at 15 years).
Likewise, the cumulative incidence of SRC reduced
slightly when dual antibody subjects were excluded. At
15 years this was 6% in the whole group of ACAþ dif-
fuse patients, and reduced to 4% after exclusion of
patients with multiple antibodies. This did not change
the overall results of the comparison with non-ACA dif-
fuse and ACAþ limited patients (P¼ 0.09). Estimates of
the cumulative incidence of PH were also unaffected by
exclusion of dual antibody patients, with a cumulative
incidence of PH in the ACAþ diffuse group not different
from the other two groups (P¼ 0.59). At 5, 10 and
15 years of follow-up, this was 9, 12 and 27%,
respectively, in the whole ACAþ diffuse group and 10,
14 and 26% in the group excluding dual antibodies.
Discussion
This study confirms that ACAþ dcSSc is uncommon and
has a distinct clinical phenotype. Among all CTDs SSc
is relatively rare and, to our knowledge, there are no
studies that specifically describe demographic and clini-
cal characteristics of SSc ACAþ diffuse patients.
Similar to our study, the frequency of ACAþ diffuse is
low in the majority of the SSc registers. In a recent
report from the European Scleroderma Trials and
Research group (EUSTAR) cohort, 7.2% of the ACAþ
patients presented the diffuse SSc subset [3]. In the
Pittsburgh Scleroderma Database, from a cohort of
1432 patients, 291 were ACAþ, 5% of them with dcSSc
[1]. In another cohort from the German Scleroderma
Registry, from 863 patients, ACA was detected in 310
(35.9%) patients, 12 of them (6.9%) with dcSSc [9].
Autoantibodies in SSc are known to be specific
and associated with significant clinical manifestations.
FIG. 1 Comparison of survival and cumulative incidence of organ complications between the three groups
(A) Comparison of survival rate from disease onset between ACAþ diffuse, ACAþ limited and non-ACA diffuse
patients. (B–D) Cumulative incidence of interstitial lung disease (B), pulmonary hypertension (C) and renal crisis (D) in
ACAþ diffuse, ACAþ limited and non-ACA diffuse patients. gr: group.
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ACA is one of the hallmark antibodies in scleroderma,
targeting centromere protein-B, an alphoid DNA binding
protein [2]. ACAs are classically associated with lcSSc,
being protective for severe organ involvement, such as
cardiac SSc, SRC and ILD [1, 2]. In the Pittsburgh
Scleroderma Database, in ACAþ patients, 4% had car-
diac disease, 1% had SRC and 6% had severe ILD,
contrasting with 16% of cardiac disease, 10% of SRC
and 23% of ILD in patients with ATAþ [1]. Likewise, in
the German cohort, patients with ACAs had a lower fre-
quency of ILD [odds ratio (OR) ¼ 0.18 (95% CI 0.12,
0.26), P<0.0001] and cardiac involvement [OR ¼ 0.51
(95% CI 0.32, 0.81), P¼0.0033]. Furthermore, ACAþ
patients were older at disease onset and had more PH
[OR ¼ 1.58 (95% CI 0.36, 2.32), P<0.0001] compared
with patients carrying other SSc-related antibodies [9].
Our study corroborates these findings, as despite the
cutaneous subset, ACAþ patients had a lower incidence
of both ILD and SRC compared with ACA patients.
Coexpression of SSc-specific antibodies is rare,
although it has been increasingly recognized recently,
probably as a result of newer laboratory diagnostic tech-
niques [10, 11]. In our cohort of ACAþ diffuse patients,
five had dual antibodies that are typically associated with
dcSSc. In a EUSTAR group-based study, 0.6% of the
patients were double positive for ACA and ATA. In this
cohort, double-positive patients had more dcSSc and ILD
compared with single-positive patients for ACA, although
the incidence of ILD was not significantly different from
ATA single-positive patients [10]. Indeed, in a study by
Graf et al. [11], 14 patients (11%) were positive for multi-
ple SSc-specific autoantibodies, and their clinical
phenotype was consistent with the characteristics gener-
ally associated with the dominant autoantibody. In the
present study, our immunology laboratory reports the
dominant patterns to allow unbiased clinical judgement.
Nevertheless, sensitivity analysis excluding patients with
dual autoantibodies associated with dcSSc did not signif-
icantly change the results from the overall group.
In a study by Mierau et al. [9] reporting autoantibody
specificities and their associations in a German cohort,
anti-p25/23 antibodies were identified in a small group
of ACAþ patients (3.2% of the whole cohort). Clinical
characteristics of this subgroup of patients were heter-
ogeneous. Indeed, in that study, subgroup analysis
demonstrated that the frequency of ILD was similar
between the anti-p25/23 subgroup and the ACAþ group
as a whole (14 and 13%), with significantly reduced
odds for ILD in both groups, compared with patients
negative for these antibodies (OR ¼ 0.33 and 0.18,
respectively) [9]. However, in a study by Furuta et al.
[12] ACAþ patients with anti-p25/23 antibodies had an
increased frequency of ILD. Furthermore, in the study
by Mierau et al. [9] none of the patients with anti-p25/
p23 antibody had diffuse disease, and thus, it is not
possible to comment on the frequency of ILD in the
ACAþ diffuse subset. As this antibody is not available
in our laboratory, this association was not evaluated in
our cohort.
Disease subset may also influence disease pheno-
type. Diffuse subset in the EUSTAR database was asso-
ciated with more internal organ involvement, namely ILD
(P<0.001) and SRC (P< 0.001), than lcSSc [3]. Indeed,
in the present study, ACAþ patients with dcSSc had a
higher incidence of involvement of internal organs, such
as ILD, cardiac and SRC, compared with ACAþ limited,
despite the known protective role of ACA for these
organ complications. However, the involvement of these
organs in ACAþ diffuse was still less frequent compared
with non-ACA diffuse, which might indicate a protective
role of ACA in patients with dcSSc.
Analysis of survival in our work seems to reinforce the
protective role of ACA in patients with dcSSc. The sur-
vival rate in both ACAþ subgroups was similar irrespec-
tive of the disease subset. Interestingly, although
non-ACA diffuse patients had much higher mortality,
there was no difference between survival rates in ACAþ
diffuse and non-ACA diffuse patients. The small number
of ACAþ diffuse patients might account for these results,
or possibly, it might reflect the influence of the diffuse
subset in ACAþ patients.
In fact, some studies have demonstrated the rele-
vance of dcSSc for early organ involvement, disease
severity and survival [13, 14]. Steen et al. [13] demon-
strated that severe organ involvement in dcSSc often
occurs in the first 3 years of disease, and that improve-
ment in skin disease in early dcSSc (<3 years) is associ-
ated with better overall survival [5]. Recently, Domsic
et al. [15] concluded that patients with a rapid skin
thickness progression rate had reduced survival [OR ¼
1.72 (95% CI 1.13, 2.62), P¼0.01] and were more likely
to develop SRC [OR ¼ 2.05 (95% CI 1.10, 3.85),
P¼0.02]. In our study, ACAþ diffuse patients reached
the peak mRSS later than non-ACA diffuse patients and
developed clinical significant organ complications,
namely ILD, later. Hence, not only does ACA seem to
influence survival, but also it can possibly modulate the
evolution of organ involvement in dcSSc.
Supporting the clinical heterogeneity of SSc, some
authors argue that this is not one defined disease, but a
syndrome with different phenotypes. SSc-related clinical
characteristics and specific antibodies vary in different
countries and ethnicities [16]. Also, familial clustering of
the disease, the presence of the same SSc-specific anti-
bodies and HLA class II molecules in families of SSc
patients support the evidence that genetic factors con-
tribute to SSc pathogenesis [17]. Several reports and a
genome-wide association study in SSc showed its
association with HLA class II, IRF5, STAT4 and BANK1
[17, 18]. A strong relationship between HLA haplotypes
and specific scleroderma-related autoantibodies is also
confirmed, with ACA being associated with HLA class II
genes, namely HLA-DQB1 and HLA-DRB1 [18, 19].
These data might reflect immunogenetic heterogeneity
in ACA patients and can account for the influence of
ACA as a phenotype modifier in dcSSc.
In conclusion, the present study, based on a large
single-centre SSc cohort with uniform disease
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characteristic definitions, confirms that ACAþ diffuse is
infrequent but has a distinct clinical phenotype. Despite
the dcSSc, these patients have a more insidious onset of
skin and major organ involvement, which might represent
a therapeutic window for early intervention. We confirm
that ACA has a protective role and is associated with a
lower incidence of ILD and SRC and better survival than
expected for dcSSc. ACA, or factors determining its
development, may act as a phenotype modifier in dcSSc.
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